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Abstract 
High-dose rate brachytherapy is a type of treatment of cancer whereby a radioactive 
source is inserted directly into the tissue or its nearest vicinity for short time intervals, damaging 
the DNA of rapidly dividing cancer cells and triggering cell death. This study considers 
Ytterbium-169, a high-energy photon source, as an alternative to Iridium-192, the current HDR 
brachytherapy standard. We demonstrate that Ytterbium-169 performs as successfully as 
Iridium-192 in delivering a high, uniform dose to soft tissues, but results in an unfavorably high 
dose to bone tissue. We suggest that Ytterbium-169 is a promising target for intensity modulated 
brachytherapy.  
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2 INTRODUCTION 
2.1 PURPOSE 
The purpose of this work is to explore the use of Ytterbium-169 as a source for cervical 
brachytherapy with the goal in increasing the ratio of the dose delivered to the tumor to the dose 
absorbed by surrounding healthy tissues. In particular, this work uses a Monte Carlo simulation 
to compare the outcomes of using Ytterbium-169 to those achieved with the current industry 
standard, Iridium-192 (Lawrence et al., 2008).  
2.2 BRACHYTHERAPY 
2.2.1 BACKGROUND 
Cervical cancer is the third most common cancer in the United States, with 12,820 estimated new 
cases and 4,210 estimated deaths in 2017 (U.S. Cancer Statistics Working Group, 2016). The 5-
year survival rate for women affected by cervical cancer varies between 91% for women 
diagnosed at an early stage to 17% for those with late-stage tumors, resulting in an overall 5-year 
survival rate at 68% (U.S. Cancer Statistics Working Group, 2016). Radiotherapy remains one of 
the most effective treatments for cervical cancer and, as it is currently used to treat both early-
stage (IA2) and advanced cervical cancers, it is one of the most commonly used treatments for 
the condition (American Cancer Society, 2016) 
2.2.2 GENERAL APPROACH 
Brachytherapy is a type of cancer treatment delivered by insertion of an encapsulated radioactive 
source into the tissue of a tumor. Brachytherapy is used for a number of different cancers, 
including cervical, breast, prostate, eye, and brain cancers. An internal radiation therapy, 
brachytherapy is applied in conjunction with external beam radiation therapy and is generally 
subdivided into a low-dose rate (LDR) and high-dose rate (HDR) brachytherapy.  
HDR brachytherapy is delivered via insertion of cylindrical encapsulated pellets - “seeds” - into 
a cavity near the tumor or into the tumor directly through a plastic tube, using a steel wire 
attached to the pellet as a guiding device. The sources are packaged into small stainless steel 
capsules, and reach the size of a grain of rice. To control for differences in sources’ energies, and 
activities, a dose prescription convention is adopted. For brachytherapy of cervical cancer, 
considered this report, the International Committee on Radiation Units and Measurements’ 
Report 38 (ICRU38) outlines the most commonly applied approach to prescribing radiation 
doses to point in the in the treatment site (International Committee on Radiation Units and 
Measurements, 1985; Banerjee and Kamrava, 2014) The radiation dose in prescribed to point A 
– a point located 2 cm upwards along the main axis of the cylindrical source, and 2 cm lateral to 
the axis. Thus, prescription point A is removed from the seed by 𝑟" ≈ 2.83 cm. 
2.2.3 GENERAL PRINCIPLE 
The primary type of radiation responsible for delivering prescribed doses to tissues is radiation 
emitted from the sources in the form of high-energy photons – x-rays and gamma-rays 
(Lawrence et al., 2008). Although many medical radiation sources emit electrons, the Coulomb 
interactions that result from non-zero charge, and low energy does not allow them to travel 
through the tissues to an appreciable extent and, as a result, causes the electrons to deposit their 
energy locally, where the first interaction event between the electron and an atom of the tissues 
occurs (Jawett and Serway, 2008). High-energy photons, on the other hand, penetrate matter to a 
much greater extend, and are able to deposit their energy over longer distances. Thus, with 
respect to brachytherapy, high-energy photon-tissue interactions decide the therapeutic 
outcomes. It is, therefore, these interactions that this paper discusses. 
Although the primary focus of this work is HDR brachytherapy, the same physical principles 
guide the effects of all aforementioned brachytherapy types on tissues of the body. Photons 
emitted from a source, can interact with the atoms of the body tissues in one of three ways: 
1. Photoelectric effect 
2. Compton scattering 
3. Electron-positron pair production. 
Two factors affect the type on interaction between the body tissues and the photons: 
1. The energies of photons produced by medical nuclides fall in the range between 21 keV 
for relatively low-energy Palladium-103, to 3500 keV for high-energy Ruthenium-106 
(Rijnders, 2009).  
2. The tissues of the body are comprised primarily of elements with average atomic 
numbers of 𝑍) = 7.5 for soft tissue (dominant elements 6C, 7N, 8O) and 𝑍- = 13 for bone 
(dominant elements 6C, 8O, 15P, 20Ca). 
As Figure 1 suggests, the energies of incident photons and atomic numbers of most common 
biological elements point at Compton scattering as the characteristic process that dominates in 
high-energy photon interactions with body tissues. 
2.2.4 COMPTON SCATTERING 
Compton scattering is a type of inelastic photon scattering that occurs between a charged particle 
– an electron, in the case of brachytherapy – and a photon, and result in a decrease of photon 
energy and ionization of the electron-bearing atom. The increase in the photon wavelength 
associated with the energy loss is given by the famous relation due to Compton (Jawett and 
Serway, 2008): 
𝜆0 − 𝜆 = ℎ𝑚4𝑐 (1 − cos 𝜃 ) 
where 
 𝜆 - photon wavelength before scattering, 
 𝜆0 - photon wavelength after scattering, 
 𝜃 - scattering angle, i.e. angle between the directions of scattered and incident photon 
FIGURE 1. TYPE OR INTERACTION THAT OCCURS BETWEEN AN X-RAY OR GAMMA-RAY 
SOURCE AND ATOMS OF DIFFERENT ATOMIC NUMBERS. 
 𝑚4 - electron mass 
 𝑐 - speed of light in vacuum 
 ℎ - Plank’s constant 
The energy of the scattered photon is given by 
𝐸0 = 𝐸𝐸𝑚4𝑐= 1 − cos 𝜃 + 	1 
where 𝐸 is the energy of incident photon. 
Therefore, during Compton scattering, the energy of supplied to an electron in the atom is given 
by the following equation: 
𝛥𝐸(𝐸, 𝜃) = 𝐸 − 𝐸0 = 𝐸 1 − cos 𝜃1 − cos 𝜃 + 𝑚4𝑐=𝐸  
The probability that a particular photon with energy 𝐸 incident onto an electron will scatter at a 
specific angle 𝜃 while supplying energy 𝛥𝐸 to the electron is given by Klein-Nishina 
distribution. Since scattering is fundamentally a quantum-mechanical event, the exact energy left 
to an electron cannot be predicted exactly for any individual interaction.  
It is clear, however, that the energy of an electron after Compton scattering cannot exceed the 
energy of the incident photon. Therefore, after ionization from Compton scattering with high-
energy photons produced by most medical radiation sources, ejected electrons will have energies 
no more than approximately 1 MeV. Supplied with this energy, electrons will travel over a 
distance of under 5 mm before depositing all of their energy in the tissue. Given the Iridium-192 
and Ytterbium-169 average photon energies of 387.5 keV and 92.7 keV, respectively, electrons 
will deposit their energy over even smaller distances (Rijnders, 2009; Chu et al., 1999). Thus, for 
the purposes of the paper, all traveling electrons are assumed to deposit their energy locally, as 
stated above. 
2.2.5 PHOTOIONIZATION 
In addition to Compton scattering, photons with energies below 100 keV can interact with 
heavier elements of the body, such as 15P and 20Ca particularly abundant in bones and result in 
photoionization of atoms of those elements. In this case, a photon will be fully absorbed, and an 
electron will be ejected from the atom participating on the interaction (Jawett and Serway, 2008). 
For the reason given above, this will result in all of the photon energy being deposited locally, at 
the site of interaction. 
2.2.6 IRIDIUM-192 
Currently, the standard source for HDR cervical brachytherapy is Iridium-192 (Table 1). The 
energies and intensities of photons emitted by Iridium-192 are given in blue in figure Figure 2. 
Iridium-192 is produced from iridium metal by neutron activation in nuclear reactors. Its energy 
spectrum and high specific activity makes it a good source for HDR brachytherapy: (Lawrence et 
al., 2008) 
1. Iridium photons interact with tissues via Compton scattering and are not energetic enough 
to travel unobstructed delivering excessive dose to healthy tissues 
2. A small Iridium-192 source is capable of delivering high enough dose rate necessary for 
HDR brachytherapy. 
TABLE 1. PHYSICAL PROPERTIES OF IRIDIUM-192 (MEDICH AND MUNRO, 2007). 
Iridium-192 Physical Properties 
Half-life 73.8 days 
Decay Mode 𝛽, 𝛾, 𝜀  
Production mode  Thermal Neutron Activation	
Average energy 387.5 keV 
 
2.2.7 YTTERBIUM-169 
Ytterbium-169 – a radioactive isotope of Ytterbium. Produced similarly to Iridium-192, but 
displays a different radiation spectrum. Most of its photon energies are in the range between 40 
and 100 keV, with the most intensive photon emitted with an energy of 50.7 keV. The average 
energy of Ytterbium-169 photon spectrum is 92.7 keV – more than 4 times lower than that of 
Iridium-192. Yet, as the energies of Ytterbium-169 photons fall in the range described above, 
Compton scattering still remains the characteristic interaction type between Ytterbium-169 
photons and tissues of the body allowing the material to distribute the radiation dose in a way 
similar to Iridum-192 (Medich et al., 2006) 
Similar to Iridium-192, Ytterbium-169: 
1. Delivers the dose via Compton scattering and absorption of high-energy photons in the 
tissues of the body. 
2. Has high specific activity and is capable of delivering high dose rate necessary for HDR 
brachytherapy. 
Due to its lower energy spectrum, Ytterbium-169 possesses the following advantages over 
Iridium-192 for HDR brachytherapy: 
1. Ytterbium is more easily shielded and is safer to handle. 
2. Ytterbium can be combined with intensity modulation techniques such as partial seed 
shielding to improve the dose control. 
 
TABLE 2. PHYSICAL PROPERTIES OF YTTERBIUM-169 (MEDICH ET AL., 2006) 
Ytterbium-169 Physical Properties 
Half-life 32 days 
Decay Mode 𝜀  
Production Mode Thermal Neutron Activation 
Average energy 
50.7 KEV 
  
2.2.8 PROBLEM STATEMENT 
It has been shown that increased dose to the prescription point A correlates with an increased 
local control over the tumor, and, therefore, improved clinical outcomes (Eifel et al., 1994). 
Meanwhile, an increased dose to the prescription point is traditionally associated with a higher 
dose to the healthy tissues surrounding the tumor (Lawrence et al., 2008). Hence, finding ways 
to increase the dose delivered to the prescription point without the toll of overdosing the tissues 
FIGURE 2. PHOTON EMITTION SPECTRUM OF YTERBIUM-169 (RED) AND IRIDIUM-
192 (BLUE) WITH RELATIVE INTENSITIES. AS SEEN ON THE GRAPH, YTTERBIUM 
SPECTRUM LIES ALMOST ENTIRELY IN THE LOWER ENERGY REGION THAN THAT OF 
IRIDIUM, WITH THE MOST INTENSIVE PEAR AT 50.7 KEV. IRIDIUM, ON THE OTHE 
HAND, EMITS PHOTONS OF HIGHER ENERGIES, WITH THE MOST PROMINENT PEAK 
AT 316.51 KEV. (CHU ET AL., 1999) 
outside the target is an attractive objective in brachytherapy research. Having introduced two 
radiation sources, Iridium-192 currently used for HDR brachytherapy and Ytterbium 169, this 
study models the use of Ytterbium-169 for HDR brachytherapy and compares the outcomes to 
the use of Iridium-192. 
2.3 MODELING 
To be applicable, the model of the problem had to simulate the following elements of the 
process: 
1. Female anatomy and tissue arrangement. Cervical brachytherapy targets specific 
volumes within female anatomy that span different tissues with varied elemental 
composition. Brachytherapy seeds are placed at specified location within the geometric 
framework defined by the anatomy, and the photons emitted from the sources interact 
differently with tissues with different elemental compositions. The simulation had to 
accounted for the complex arrangement of materials inside the body. 
2. Radioactive sources. The simulation had to include radiation sources of proper sizes, 
geometries, and composed of specified material with known decay modes and emission 
spectra. 
3. Interactions between emitted particles and body tissues. The simulation had to model 
primary photon-tissue interactions between the photons emitted from the seed and atoms 
of the surrounding tissues, as well as particles produced as a result of the interactions.  
Since each source photon participates in numerous interactions during its lifetime, Monte Carlo 
method was used to model the problem. 
2.3.1 MONTE CARLO METHOD 
Monte Carlo method is a numerical technique particularly effective to solve model statistical 
processes – processes with outcomes determined by random sampling from a probability 
distribution. The method is frequently applied to problems involving large numbers of 
statistically determined events. Due to the large number of particle-particle interactions involved 
in modeling brachytherapy, and due to the probabilistic outcomes of those interactions, Monte 
Carlo model was used to model the treatment. 
During the Monte Carlo simulation, each of the following physical parameters is sampled from 
their respective distributions (𝑖 - particle index) 
1. 𝒓G,H	 -  starting position of the particle within the source 
2. 𝒗J,K - initial velocity of the particle 
3. 𝑑G,𝒓 - distance traversed before the next interaction, depends on the medium 
4. 𝒗G,𝒓 - “new” velocity of the particle after the interaction, 
where 𝒓 is coordinate vector of the point where the particle interacts with the surrounding 
matter. 
In addition to the parameters above, the type of interaction that occurs at position 𝒓 is also 
determined probabilistically and depends on the energy of the particle being tracked and the 
particle with which it interacts. In this manner, Monte Carlo algorithm resamples the parameters 
of interest to construct the particles’ trajectory, segment by segment.  
In terms of modeling brachytherapy, the Monte Carlo method entails the following steps: 
1. Generate a photon at a point within the volume of the source with a starting energy drawn 
from a discrete distribution shown in Figure 2. 
2. Sample the distance traveled by the photon before interaction. Determine the type of 
interaction from a distribution. For all particles that exist after the interaction, i.e. 
scattered photons and/or ejected electron, repeat the steps to determine all trajectory 
segments for all generated particles to the boundary of the problem space.  
The Monte Carlo method generates a large number of instances of the physical process, such as 
photons leaving the radiation source, and computes the average of the parameter on interest, e.g. 
dose rate delivered to a voxel of the model. 
2.3.2 MONTE CARLO N-PARTICLE TRANSPORT (MCNP) CODE  
MCNP6 Code is an implementation of the Monte Carlo method designed specifically to model 
nuclear events, transport, and interactions of subatomic particles developed at Los Alamos 
National Laboratory (LANL). MCNP6 allows the user to define the following problem 
parameters (Goorley et al., 2012): 
1. Problem universe 
a. Geometry (i.e. anatomy) of bodies in the problem, such as the anatomy and 
sources of radiation. Surfaces separating the 3D volumes are defined defined by 
second degree elliptic and fourth degree toroidal surfaces. Volumes in geometry 
are defined with union and intersection logical operators. 
b. Elemental composition of materials that make up the geometry, i.e. the elemental 
composition of tissues of the body. 
c. Density of the materials in the problem geometry. 
2. Radioactive source 
a. Radiation spectrum 
b. Source placement 
3. Dose tally 
a. Method to count contributions from modeled particles 
b. Type of contributions (e.g. dose rate) 
4. Simulated physics of interactions 
a. Type on interaction that are allowed to happen in the simulation. 
The details of using the MCNP6 Code can be found in the MCNP6 User Manual (Goorley et al., 
2012) and are beyond the scope of this report. 
The MCNP6 Code was used as the modeling software because: 
1. Frequently used for simulation in medical physics; 
2. Provides extensive libraries with material properties; 
3. Describes physical interaction that occur in the energy range between 10 keV and 1000 
keV, which encompasses the energy range of the interaction from Iridium-192 and 
Ytterbium-169 brachytherapy sources; 
4. Provides an industry-standard phantom of an adult female – MIRD Phantom (Xu and 
Exkerman, 2009) – necessary for cervical HDR brachytherapy simulations. 
2.3.3 MIRD PHANTOM 
The MIRD Phantom developed by Eckerman et. al is a simplistic model of a female human 
body. The Phantom consists of 35 discrete cells – organs – filled with one of the 4 types of 
media: air, soft tissue, bone tissue, or lung tissue. Cross-sectional images of the model 
implemented in the MCNP Code are shown in Figures 3 and 4. 
 FIGURE 3. FRONTAL VIEW OF THE MIRD PHANTOM TORSO. YELLOW - SOFT TISSUE, 
GREEN - LUNG TISSUE, TURQUOISE - BONE TISSUE, BLUE - AIR. 
 FIGURE 4. SAGITTAL VIEW OF THE MIRD PHANTOM. THE PHANTOM IS FACING 
LEFTWARDS. YELLOW - SOFT TISSUE, TURQUOISE - BONE TISSUE, BLUE - AIR. 
 
The organs affected by cervical brachytherapy are the cervix, uterus, bladder, sigmoid, and 
rectum. The position, shape, and composition of the organ cells in the MIRD Phantom 
coordinate space are given in Table 3. 
TABLE 3. EQUATIONS OF 2D-SURFACES THAT DEFINE MAJOR ORGANS CONSIDERED IN THE 
SIMULATION, AND THE DESCRIPTION OF THE VOLUMES DEFINED BY THOSE SURFACES. 
UNITS OF LENGTH, WHERE APPROPRIATE, ARE CENTIMETERES. 
Organ Shape Boundary Equation Organ Volume 
Space 
Uterus Sliced 
ellipse  
(wall):  75.61172	𝑥= + 14.65741 𝑦 + 1.96 =+ 192.0081	 𝑧 − 12.62 == 461.2995 
(plane): 𝑦 = −4.77 
Inside the wall and 
to the right of cut-
off plane (i.e. 𝑦 ≥−4.77) 
Bladder Ellipse (wall):  110.4979	𝑥= + 176.3504 𝑦 + 4.41 =+ 208.2999	 𝑧 − 7.21 == 2014.6979 
Inside the wall 
Sigmoid Parts of two 
tori 
(upper torus): 𝑦=1.18=
+ 𝑥 − 2.09 = + 𝑧 − 7.86 = − 5.16 =1.76=− 1 = 0 
(lower torus): 
Inside quarter-
circle segments of 
upper and lower 
torus, between the 
place 𝑧 = 0 and 𝑧 = 7.86. 
𝑦=1.18= + 𝑥 − 2.59 = + 𝑧= − 2.70 =1.76=− 1 = 0 
 
Cervix 
(tumor)1 
Sphere (sphere): 𝑥= + 𝑦 − 4.5 = + 𝑧 − 9.915 = = 6.25 Inside the sphere 
 
2.4 HYPOTHESIS 
This work attempted to establish that Ytterbium-169 used for HDR brachytherapy of cervical 
cancer: 
1. Delivers more uniform dose rate to the tumor of the cervix and results in a larger ratio of 
tumor-to-healthy tissue dose compared to brachytherapy with Iridium-192 source of the 
same geometry. 
2. Delivers an equivalent or smaller dose to the organs at risk, i.e. uterus, bladder, sigmoid, 
and rectum, as an Iridium-192 source of the same geometry.  
The hypothesis was tested using a Monte Carlo simulation conducted with LANL MCNP6 Code. 
In particular, the simulation was used to compare the doses delivered to a cervical tumor model – 
a sphere with 2.5 cm radius – and organs at risk by a standard-shaped Ytterbium-169 and 
                                                   
1 See methodology for placement guidelines. 
Iridium-192; construct dose rate intensity plots and dose-volume histograms for the tumor and 
organs at risk.  
3 METHODOLOGY 
The brachytherapy treatment was modeled with MCNP6, using MIRD Phantom to represent an 
adult female, and custom-defined geometry to represent HDR brachytherapy radiation sources. 
Two MCNP simulations were run with identical geometries and different source parameters: one 
corresponding to a Ytterbium-169, and the other – to the Iridium-192 source. The number of 
particle histories simulated in each run was 𝑛𝑝𝑠 = 5000000. For each run, the dose rate 
delivered by the radiation sources to the body tissues was estimated using the same 3-
dimensional mesh (array-like) tallies that sored the dose rate measurements for every voxel 
defined in the tally.  
If was assumed that, given the energies of the particles involved in the modeled process, photons 
are the only particles capable of traveling significant distance, while electron produced as a result 
of photon-tissue interactions were not tracked by the code and were simulated as depositing their 
whole energy locally. 
3.1 MIRD PHANTOM 
In the MCNP coordinate space, the phantom is oriented upright with the main axis of the 
cylindrical torso aligned with the z-axis if the coordinate frames. The phantom is facing the 
negative y-direction. Thus, the coordinate planes represent the following cross-sections of the 
phantom: 
xy-plane – Transverse plane  
 yz-plane – Sagittal plane 
 xz-plane – Frontal (or Coronal) plane 
3.2 HDR BRACHYTHERAPY SOURCE 
The brachytherapy source parameters were take from (Medich et al., 2006; Medich and Munro, 
2007). The source was modeled as a right cylinder with base radius 𝑟)- = 0.0365	𝑐𝑚 and length ℎ) = 0.360	𝑐𝑚 along the main axis. The source was encapsulated in a stainless steel shell 0.017	𝑐𝑚 thick. A 0.010	𝑐𝑚 thin air layer was left between the inner seed and the stainless steel 
encapsulation. The surface cards for the seed assembly were defined in an auxiliary coordinate 
system, in which the cylindrical source was oriented along the 𝑧′-axis of the coordinate frame, 
with the stainless steel shell spanning from 𝑧 = 0	𝑐𝑚 to 𝑧 = 0.414	𝑐𝑚.  
The auxiliary coordinate system was shifted to position the source in the pelvic area near the 
posterior side of the uterus, at the hypothetical location of the cervix approximately 2 cm to away 
from the internal orifice of the uterus. The operations applied to the auxiliary coordinate system 
to shift it into the its final location are as follows: 
1. The origin 𝑂′ of the auxiliary coordinate frame was translated to the point 𝑝 =0, 4.5, 9.915  in the global MCNP coordinate frame. 
2. Then, the auxiliary coordinate system was actively rotated around the 𝑥0-axis over angle 𝜃 = Z[ as defined by the matrix: 
𝑅 = 	 1 0 00 cos 𝜋4 − sin 𝜋40 sin 𝜋4 cos 𝜋4 	
As a result of the transformation, the cylindrical seed was positioned such that it’s main 
axis lied entirely in the sagittal plane, at a 45° angle above the hypothetical line of sight 
of the phantom.  
The MCNP code block with the definition of the source is given in Figure 3. 
 
 
Cell 9902 containing the brachytherapy seed was defined as the only source used in the 
simulation. For each of the two MCNP runs, cell 9902 was endowed with Ytterbium-169 or 
Iridium-192 photon emission energy spectrum (both spectra shown in Figure2). The detailed 
photon energy distributions are shown in Table 4 – for Ytterbium-169, and Table 5 – for Iridium-
192. Figure 4 displays the MCNP code used to define the sources in the simulation software. 
(cell card block) 
9900 13 -7.80 (-9001 9002) imp:p=1 $ steel shell 
9901 2 -0.00129 -9002 9003 imp:p=1 $ air layer inside the seed 
9902 11 -6.90 -9003 imp:p=1 $ Y-169 (or Ir-192) seed 
(surface card block) 
9001 900 rcc 0 0 0 0 0 0.414 0.0635 $ outer shell surface 
9002 900 rcc 0 0 0.017 0 0 0.380 0.0465 $ inner shell surface 
9003 900 rcc 0 0 0.027 0 0 0.360 0.0365 $ Ytterbium Oxide surface 
(transformation card from data card block) 
*tr900 0 4.5 9.915 0 90 90 90 45 -45 90 135 45 $ seed position transform 
FIGURE 5. BRACHYTHERAPY SOURCE GEOMETRY DEFINITION IN MCNP CODE. IR-192 
SEED WAS DEFINED IN THE SAME WAY, WITH A DIFFERENT MATERIAL NUMBER APPLIED 
IN CELL 9902 DEFINITION. FOR CONVENIENCE, THE SEED GEOMETRY WAS DEFINED IN 
A SEPARATE COORDINATE SYSTEM, WHICH WAS THEN SHIFTED INTO THE PROPER 
POSITION VIA A COORDINATE TRANSFORMATION CARD. 
TABLE 4. YTTERBIUM-169 PHOTON ENERGY SPECTRUM USED FOR THE MCNP 
SIMULATION. WEIGHTED AVERAGE ENERGY OF THE SPECTRUM IS 92.7 KEV (MEDICH ET 
AL., 2006) 
 
 
 
 
 
 
 
 
 
Energy (keV) Intensity (%) 
49.5 53.2 
50.7 94.0 
57.6 29.5 
59.1 8.2 
63.1 44.2 
93.6 2.6 
109.8 17.5 
118.2 1.9 
130.5 11.3 
177.2 22.2 
198.0 35.8 
162.1 1.7 
307.7 10.1 
 TABLE 5. IRIDIUM-192 PHOTON ENERGY SPECTRUM USED FOR THE MCNP SIMULATION. 
WEIGHTED ENERGY OF THIS ENERGY SPECTRUM IS 387.5 KEV (MEDICH AND MUNRO, 
2007). 
 Energy (keV) Intensity (keV) 
61.49 1.20 
63.00 2.07 
64.12 2.65 
66.83 4.53 
71.08 0.24 
71.41 0.46 
73.36 0.16 
75.37 0.53 
75.75 1.03 
77.83 0.37 
136.34 0.18 
201.31 0.47 
205.80 3.30 
283.27 0.26 
295.96 28.67 
308.46 30.00 
316.51 82.81 
373.49 0.72 
416.47 0.66 
468.07 47.83 
484.58 3.18 
489.04 0.44 
588.58 4.52 
604.41 8.23 
612.47 5.31 
884.54 0.29 
 The composition of materials used to model components of the seed assembly are shown in 
Table 6. 
TABLE 6. ATOMIC COMPOSITION OF MATERIAL IN BRACHYTHERAPY SEED ASSEMBLY. 
Material Atom Atomic Fraction 
Air 
(density 𝜌" = 0.00129 
g/cm3) 
Nitrogen 0.80 
Oxygen 0.20 
c  Ytterbium-169 Source 
SDEF cel=9902 erg=d1 x=d2 y=d3 z=d4 par=2 
SI1 L 0.0495 0.0507 0.0576 0.0591 0.0631 0.0936 &  
 0.1098 0.1182 0.1305 0.1772 0.198 0.2611 0.3077  
SP1 53.2 94.0 29.5 8.2 44.2 2.6 17.5 1.9 11.3 22.2 35.8 1.7 10.1 
SI2 -0.0365 0.0365 
SP2 0 1 
SI3 4.200 4.507  
SP3 0 1 
SI4 9.908 10.215  
SP4 0 1 
c  Iridium-192 Source    
SDEF cel=9902 erg=d1 x=d2 y=d3 z=d4 par=2 
SI1 L 0.06149 0.06300 0.06412 0.06683 0.07108 0.07141 0.07336 & 
  0.07537 0.07575 0.07783 0.13634 0.20131 0.20580 0.28327 & 
  0.29596 0.30846 0.31651 0.37349 0.41647 0.46807 0.48458 & 
  0.48904 0.58858 0.60441 0.61247 0.88454 
SP1 1.20 2.07 2.65 4.53 0.24 0.46 0.16 & 
  0.53 1.03 0.37 0.18 0.47 3.30 0.26 & 
  28.67 30.00 82.81 0.72 0.66 47.83 3.18 & 
  0.44 4.52 8.23 5.31 0.29 
SI2 -0.0370 0.0365 
SP2 0 1 
SI3 0.6 1.1  
SP3 0 1 
SI4 9.81 10.31 
SP4 0 1 
FIGURE 7. MCNP SOURCE ENERGY SPECTRUM DEFINITION USED IN THE SIMULATION. 
Stainless Steel 
(density 𝜌bb = 7.80 g/cm3) Carbon 0.0008 Silicon 0.0100 
Phosphorus 0.0005 
Sulfur 0.0003 
Chromium 0.1900 
Manganese 0.0200 
Iron 0.6859 
Nickel 0.0925 
Ytterbium-169 
(density 𝜌c = 9.17 g/cm3) Ytterbium 0.40 Oxygen 0.60 
Iridium-192 
(density 𝜌de = 22.4 g/cm3) Iridium 0.40 Oxygen 0.60 
 
The MCNP code with the material definition cards is given in Figure [FIGURE NUMBER]. 
3.3 TALLIES 
The dose rate delivered to tissues in the vicinity of the source was obtained from the MCNP6 
Monte Carlo simulation using a Cartesian TMESH tally of type 3. This TMESH tally is a 3-
m2  7000 0.8 8000 0.2  $ air 
m11   70000.04p 0.4000 8000.04p 0.6000 $ Y-169 oxide (density -9.17)   
m12  77000.04p 0.4000 8000.04p 0.6000 $ Ir-192 oxide (density -22.4) 
m13   6000.04p 0.0008 14000.04p 0.0100 15000.04p 0.0005 &  
  16000.04p 0.0003 24000.04p 0.1900 25000.04p 0.0200 &  
  26000.04p 0.6859 28000.04p 0.0925    $ Steel (density -7.80) 
FIGURE 8.  MATERIAL DEFINITIONS IN MCNP CODE FOR THE MATERIALS USED IN THE 
SOURCE ASSEMBLY. MATERIAL 1 - AIR, MATERIAL 11 - YTTERBIUM-169 OXIDE, 
MATERIAL 13 - STAINLESS STEEL. 
dimensional array of dose rate values, in units of MeV/(cm3 n), delivered to the voxel associated 
with the array entry. The coordinate boundaries of the voxels corresponding to array entries are 
defined by the user, and are output in the TMESH output file as three 1-dimensional arrays with 
coordinates along x-, y-, and z-axis.  
The TMESH tally used in the simulation was implementer with 200 bins, spanning from -10 cm 
to 10 cm along each coordinate direction, with 0.1	𝑐𝑚 spacing for each bin, and 0.001	𝑐𝑚f 
volume associated with every 3D voxel. The TMESH tally was defined in the coordinate system 
of the source in the coordinate system associated with the source and shifted along with it via the 
coordinate transformation card used in defining the source.2 The same TMESH tally was used 
for simulating both Ytterbium-169 and Iridium-192. The MCNP6 code block used to define the 
tally is shown in Figure 9. 
The TMESH tally output file was processed with a Python script and the following quantities 
were obtained: 
                                                   
2 I.e. the TMESH tally bin grid did not align with the coordinate grid of the system associated 
with the MIRD phantom. 
RMESH123 TRANS 900 
    CORA123 -10 199I 10   
    CORB123 -10 199I 10   
    CORC123 -10 199I 10     
ENDMD 
 
FIGURE 9. MCNP6 TMESH TALLY OF TYPE 3 CODE BLOCK. THE SAME 
TALLY WAS USED FOR SIMULATING BOTH YTTERBIUM-169 AND 
IRIDIUM-192. 
1. 𝑃 = 𝑝Ghi = 𝑥G, 𝑦h, 𝑧i  - set of center points of the rectangular voxels defined in the 
TMESH block in the MCNP6 input file.  
2. 𝑉Ghi = 0.001	𝑐𝑚f – voxel volume associated with every point 𝑝Ghi ∈ 𝑃. 
3. 𝐼 𝑝Ghi  – dose rate measurements, in units of 𝑀𝑒𝑉/(𝑐𝑚f ∙ 𝑛𝑝𝑠), obtained at points 𝑝Ghi ∈ 𝑃. 
In addition, the dose rate unit conversion factor 𝛼re for soft tissue was obtained using the soft 
tissue density 𝜌)s = 1.04	𝑔/𝑐𝑚f defined in the MIRD phantom MCNP code: 
𝛼re = 1.54056 ∙ 10uvK	(𝐽 ∙ 𝑐𝑚f)/(𝑀𝑒𝑉 ∙ 𝑘𝑔) 
3.4 DORE RATE INTENSITY 
The dose rate function 𝐺 𝑝Ghi = 	𝛼re	𝐼 𝑝Ghi  was renormalized to the dose measured at the 
prescription point A 𝑝" = (0, 2, 2): 
𝐺z(𝑝Ghi) = 𝐺 𝑝Ghi𝐺 𝑝"  
Renormalized dose rate function 𝐺z 𝑝Ghi  was plotted in the two planes: 
1. Plane transverse to the axis of the cylindrical source, defined by the bases 𝑡| = (1, 0, 0) 
and 𝑡} = (0, 1/ 2, 1/ 2). 
2. Sagittal plane of the phantom displaying the longitudinal cross-section of the source, and 
defined by the bases  
3.5 DOSE RATE MAP 
The dose rate function 𝐺 𝑝Ghi = 	𝛼re	𝐼 𝑝Ghi  was renormalized to the dose measured at the 
prescription point A 𝑝" = (0, 2, 2): 
𝐺z(𝑝Ghi) = 𝐺 𝑝Ghi𝐺 𝑝"  
Renormalized dose rate function 𝐺z 𝑝Ghi  was plotted ass a heat man in the two planar sections 
of the MIRD phantom: 
3. Plane transverse to the axis of the cylindrical source, defined by the bases 𝑡| = (1, 0, 0) 
and 𝑡} = (0, 1/ 2, 1/ 2). 
4. Sagittal plane of the phantom displaying the longitudinal cross-section of the source, and 
defined by the bases 𝑙| = (0, 1, −1) and 𝑙} = (0, −1, 1). 
Built-in Python linear interpolation was used to find values dose rate values between the points 𝑃 
of the mesh. 
3.6 DOSE VOLUME HISTOGRAMS 
The dose-volume histogram was constructed for the tumor, 5 cm in diameter and centered at the 
source; and uterus, located approximately 7 cm away from the source (center), with the point of 
the uterus closest to the source located 2.4 cm away from the source. 
For each of the two targets, the histograms were constructed on the following way: 
1. A set of points 𝑃s ⊂ 𝑃 inside the volume of the target tissue was selected. 
2. The relative volume 𝑉e(𝐷) of the target tissue receiving a dose equal to or above 𝐷 was 
found using the formula: 
𝑉e 𝐷 = 𝑁 𝐺z 𝑝 ≤ 𝐷 ∙ 𝑣∈ 𝑣∈  
where 𝑁(𝐺z ≤ 𝐷) is the counting function that returns 1 whenever the condition given 
as the arguments is satisfied: 𝑁 𝑥 ≤ 	𝑎 = 1, 𝑥 ≤ 𝑎0, 𝑥 > 𝑎 
Plots of the relative volume function, or dose volume histograms were constructed for the tumor 
and uterus from simulations with Ytterbium-169 and Iridium-192.  
4 RESULTS 
The MCNP6 TMESH type 3 tally output was converted into the dose rate and the dose rate 
function 𝐺z(𝑥G, 𝑦h, 𝑧i), normalized to the prescription dose at point A was obtained. 
4.1 DOSE RATE MAP 
The MCNP6 TMESH type 3 tally output was converted into the dose rate and the dose rate 
function 𝐺z(𝑥G, 𝑦h, 𝑧i), normalized to the prescription dose at point A was obtained. Figure 11 
shows the 2-dimensional heat map of the normalized dose rate function 𝐺z 𝑥G, 𝑦h, 𝑧i  in the 
plane perpendicular to the main axis of the cylindrical seed at half-seed-length point with 𝑧i =0.15. The schematic drawing of the plane plotted in Figure 11 is shown in Figure 10. The color 
scheme represent the values attained by 𝐺z 𝑥G, 𝑦h, 𝑧i = 0.15  and arranged in color-coded bins 
between 0 and 1 prescription doses. The seed is positioned in the center of the plot and is 
surrounded primarily by soft tissue. Volumes outlined in white are filled with bone tissue. 
 FIGURE 10. SCHEMATIC DRAWING OF THE MIRD PHANTOM DEPICTING THE PLANE OF THE 
PLOT AS A DOTTED RED LINE. 
 
 
FIGURE 11. HEAT MAP OF THE DOSE RATE FUNCTION NORMALIZED TO THE PRESCRIPTION 
DOSE AT POINT A. THE PLANE OF THE PLOT IS TRANSVERSE TO THE BRACHYTHERAPY 
SEED AND SPLITS THE SEED IN TWO IDENTICAL CYLINDERS. THE WHITE DOT MARKS THE 
LOCATION OF THE SEED. VOLUMES OUTLINED IN WHITE ARE BONE TISSUE; ALL OTHER 
VOLUMES SHOWN ON THE PLOT ARE SOFT TISSUE, WITH THE EXCEPTION OF THE SEED. 
 
As the figure suggests, there the dose rate delivered to the target – tumor of 5 cm radius – was 
the same for Ytterbium-169 and Iridium-192 seeds, with the tumor receiving at least one 
prescription dose in all points plotted in this cross-section. Ytterbium-169 delivered a significant 
dose to the pelvic bone as some of the bone sections closest to the source receiving more than 
one prescription dose. Iridium-192 delivered a smaller dose to the pelvis which did not exceed 
0.7 of the prescription doses.  
Similar to the transverse plot, the longitudinal cross-section plot (Figures 12) reveals similar 
outcomes. Most of the tumor volume received at least the prescription dose with both Ytterbium 
and Iridium, while Ytterbium-169 delivered a greater dose to the pelvic bone.  
 
FIGURE 12. HEAT MAP OF THE DOSE RATE FUNCTION NORMALIZED TO THE PRESCRIPTION 
DOSE AT POINT A. THE PLANE OF THE PLOT ALIGNS WITH THE SAGITTAL PLANE OF THE 
PHANTOM AND SPLITS THE BRACHYTHERAPY SEED LONGITUDINALLY, AS SHOWN IN. THE 
WHITE DOT MARKS THE LOCATION OF THE SEED; WHITE DASHED LINE SHOWS THE AXIS OF 
THE CYLINDRICAL SOURCE. VOLUMES OUTLINED IN WHITE ARE BONE TISSUE; ALL OTHER 
VOLUMES SHOWN ON THE PLOT ARE SOFT TISSUE, WITH THE EXCEPTION OF THE SEED. 
4.2 DOSE VOLUME HISTOGRAMS 
After the normalized dose rate function 𝐺z(𝑥G, 𝑦h, 𝑧i) was obtained for all tally voxels described 
by points 𝑃 = 	 𝑥G, 𝑦h, 𝑧i , the dose volume histograms for the 5 cm spherical tumor and uterus 
were computed.  
Figure 13 shows the dose-volume histogram for the tumor. Ytterbium-169 (blue) performed as 
well as Iridium-192 (red), delivering at least the prescription dose to almost the entire volume of 
the tumor phantom.  
 
FIGURE 13. DVH HISTOGRAM FOR 5-CM SPHERICAL TUMOR PHANTOM WITH THE SEED 
PLACED DIRECTLY IN THE CENTER. 
Figure 14 displays the dose-volume histogram for the uterus. Ytterbium-169 and Iridium-192, as 
seen from the figure, delivered equivalent doses to the organ. In addition, both sources did not 
exceed the recommended maximal dose to the organ. 
 
FIGURE 14. DVH HISTOGRAM FOR THE UTERUS DEFINE IN MIRD PHANTOM. 
5 DISCUSSION 
Ytterbium-169 is an an attractive target for high-dose rate brachytherapy research as an 
alternative to Iridium-192. The Monte Carlo simulation analysis of cervical brachytherapy with 
Ytterbium-169 and Iridium-192 performed in this study suggests that Ytterbium delivers at least 
as uniform a dose to soft tissues of the therapeutic target, and an equivalent, dose the uterus – the 
closest organ at risk – as the current clinical standard Iridium-192.  
In contrast to Iridium-192, however, Ytterbium deposits higher doses in the bones near the 
tumor, most likely due to the photoelectric interactions between its lower energy photons and 
electrons of Phosphorus, Calcium, and other relatively heavy elements abundant in bone tissue. 
Due to the high radio-resistance of bone tissue, the negative impact of the increased dose to the 
bone can be a potential can be outweighed by the advantages in shielding of Ytterbium-169 
compared to Iridium-192. 
6 CONCLUSION AND FUTURE WORK 
This work investigated using Ytterbium-169 for high-dose rate brachytherapy used in treatments 
of cervical cancers. It has shown that the dose delivered to the tumor is at least equivalent to that 
delivered with Iridium-192 without an increase in the dose to the soft-tissue equivalent organs-
at-risk. 
The lower photon emission energy spectrum of Ytterbium-169 was shown to result in greater 
dose delivery to the bone tissue – an adverse therapeutic outcome compared to Iridium-192. 
Readily shielded photons emitted by Ytterbium-169, however, call for investigation Ytterbium-
169 application in intensity-modulated HDR brachytherapy. 
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